➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,231,885

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,231,885 protect, and when does it expire?

Patent 8,231,885 protects MIRVASO and is included in one NDA.

This patent has eighty patent family members in twenty-four countries.

Summary for Patent: 8,231,885
Title:Compounds, formulations, and methods for ameliorating telangiectasis
Abstract: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an .alpha.-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.
Inventor(s): DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee: Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:12/544,663
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,231,885
Patent Claim Types:
see list of patent claims
Composition; Delivery; Formulation;

Drugs Protected by US Patent 8,231,885

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,231,885

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 530185   Start Trial
Australia 2004242967   Start Trial
Australia 2005247467   Start Trial
Australia 2011231543   Start Trial
Brazil 112012024289   Start Trial
Brazil PI0511519   Start Trial
Canada 2530938   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.